Jones C, Burton M A, Gray B N
University Department of Surgery, Royal Perth Hospital, Australia.
J Pharm Pharmacol. 1989 Dec;41(12):813-6. doi: 10.1111/j.2042-7158.1989.tb06378.x.
Biodegradable albumin microspheres have been prepared with the intention of targeting doxorubicin preferentially to tumour tissue. A high-yielding microsphere manufacturing process has been developed that involved the denaturation of an aqueous protein emulsion by chemical and/or thermal crosslinking methods. Microspheres can be closely sized to a diameter of 25.3 +/- 2.6 microns with the aid of micro-sieves. The in-vitro release of doxorubicin from albumin microspheres was measured using a continuous flow system. Doxorubicin release can be sustained for up to 10 days and the rate of release could be controlled by manipulating protein denaturation conditions between the temperatures 110-135 degrees C in the presence of 0-2% glutaraldehyde. Release of doxorubicin was significantly faster in human plasma compared with isotonic saline.
已制备出可生物降解的白蛋白微球,目的是将阿霉素优先靶向输送至肿瘤组织。已开发出一种高产率的微球制造工艺,该工艺涉及通过化学和/或热交联方法使水性蛋白质乳液变性。借助微筛,微球的尺寸可精确控制在直径25.3±2.6微米。使用连续流动系统测量了阿霉素从白蛋白微球中的体外释放情况。阿霉素的释放可持续长达10天,并且通过在0-2%戊二醛存在下将蛋白质变性条件控制在110-135摄氏度之间,释放速率可以得到控制。与等渗盐水相比,阿霉素在人血浆中的释放明显更快。